AU776473C - Compositions and methods for treating cancer and hyperproliferative disorders - Google Patents

Compositions and methods for treating cancer and hyperproliferative disorders

Info

Publication number
AU776473C
AU776473C AU33972/00A AU3397200A AU776473C AU 776473 C AU776473 C AU 776473C AU 33972/00 A AU33972/00 A AU 33972/00A AU 3397200 A AU3397200 A AU 3397200A AU 776473 C AU776473 C AU 776473C
Authority
AU
Australia
Prior art keywords
growth factor
composition
peptide
mice
immunogenic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33972/00A
Other languages
English (en)
Other versions
AU3397200A (en
AU776473B2 (en
Inventor
John W Holaday
John Madsen
Stacy M. Plum
Antonio Ruiz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Casi Pharmaceuticals Inc
Original Assignee
Entremed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/266,543 external-priority patent/US6805865B1/en
Application filed by Entremed Inc filed Critical Entremed Inc
Publication of AU3397200A publication Critical patent/AU3397200A/en
Application granted granted Critical
Publication of AU776473B2 publication Critical patent/AU776473B2/en
Publication of AU776473C publication Critical patent/AU776473C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU33972/00A 1999-03-11 2000-03-10 Compositions and methods for treating cancer and hyperproliferative disorders Ceased AU776473C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/266,543 US6805865B1 (en) 1993-05-27 1999-03-11 Compositions and methods for treating cancer and hyperproliferative disorders
US09/266543 1999-03-11
PCT/US2000/006320 WO2000053219A2 (en) 1999-03-11 2000-03-10 Compositions and methods for treating cancer and hyperproliferative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004237888A Division AU2004237888B2 (en) 1999-03-11 2004-12-09 Compositions and methods for treating cancer and hyperproliferative disorders

Publications (3)

Publication Number Publication Date
AU3397200A AU3397200A (en) 2000-09-28
AU776473B2 AU776473B2 (en) 2004-09-09
AU776473C true AU776473C (en) 2005-04-14

Family

ID=23015010

Family Applications (2)

Application Number Title Priority Date Filing Date
AU33972/00A Ceased AU776473C (en) 1999-03-11 2000-03-10 Compositions and methods for treating cancer and hyperproliferative disorders
AU2004237888A Ceased AU2004237888B2 (en) 1999-03-11 2004-12-09 Compositions and methods for treating cancer and hyperproliferative disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2004237888A Ceased AU2004237888B2 (en) 1999-03-11 2004-12-09 Compositions and methods for treating cancer and hyperproliferative disorders

Country Status (6)

Country Link
EP (1) EP1156824A2 (cg-RX-API-DMAC7.html)
JP (1) JP2002538219A (cg-RX-API-DMAC7.html)
KR (1) KR20010102556A (cg-RX-API-DMAC7.html)
AU (2) AU776473C (cg-RX-API-DMAC7.html)
CA (1) CA2364503A1 (cg-RX-API-DMAC7.html)
WO (1) WO2000053219A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814744B1 (fr) * 2000-10-04 2002-11-29 Commissariat Energie Atomique Cyclopeptides, leur procede de preparation et leur utilisation comme inhibiteur ou activateur de l'angiogenese
ITRM20010088A1 (it) 2001-02-21 2002-08-21 Idi Irccs Peptide in grado di inibire l'attivita' del fattore di crescita derivato dalle piastrine (pdgf-bb) e del fattore di crescita derivato dai fi
US8021658B2 (en) 2001-05-25 2011-09-20 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7186693B2 (en) 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
FR2838444B1 (fr) * 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
US7148194B2 (en) 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
KR100768265B1 (ko) * 2005-11-10 2007-10-17 한국화학연구원 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
CN105664147A (zh) * 2007-02-07 2016-06-15 日本电气株式会社 用于癌症的治疗剂
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
FR2990352A1 (fr) * 2012-05-10 2013-11-15 Univ Paris 13 Composition immunogene comprenant un peptide derive du vegf et ses utilisations
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
CU24637B1 (es) 2019-12-24 2022-12-12 Ct Ingenieria Genetica Biotecnologia Polipéptidos que comprenden mutantes del vegf-a humano con re-arreglos de puentes disulfuro y composiciones que los contienen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0702563B1 (en) * 1993-05-27 2003-08-06 EntreMed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
EP0657175B1 (en) * 1993-12-09 2005-03-02 Centro de Inmunologia Molecular Vaccine comprising human autologous epidermal growth factor and use thereof
JPH09316000A (ja) * 1996-05-31 1997-12-09 Toagosei Co Ltd 血管新生抑制用ワクチン
CA2310252A1 (en) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens

Also Published As

Publication number Publication date
AU2004237888A1 (en) 2005-01-13
KR20010102556A (ko) 2001-11-15
CA2364503A1 (en) 2000-09-14
WO2000053219A3 (en) 2001-01-25
WO2000053219A2 (en) 2000-09-14
AU3397200A (en) 2000-09-28
JP2002538219A (ja) 2002-11-12
AU776473B2 (en) 2004-09-09
AU2004237888B2 (en) 2008-04-10
EP1156824A2 (en) 2001-11-28

Similar Documents

Publication Publication Date Title
AU776473B2 (en) Compositions and methods for treating cancer and hyperproliferative disorders
US5919459A (en) Compositions and methods for treating cancer and hyperproliferative disorders
Piguet et al. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis
EP0527787B1 (en) Method of predisposing mammals to accelerated tissue repair
EP2018871A1 (en) Immunological methods to modulate myostatin in vertebrate subjects
CZ291047B6 (cs) Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk
JPH06506205A (ja) 創傷治療
JP2011105720A (ja) Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
WO2016062227A1 (zh) 聚乙二醇化磷脂为载体的胶束多肽疫苗
US20130243822A1 (en) Composition and Method for Healing of Skin Wounds
CN101835483A (zh) 动脉粥样硬化的治疗
US6805865B1 (en) Compositions and methods for treating cancer and hyperproliferative disorders
CN1390138A (zh) 抗体作疫苗的新用途
US20040248799A1 (en) Compositions and methods for treating cancer and hyperproliferative disorders
RU2321422C2 (ru) Комбинации регулирующих рост факторов и гормонов для лечения неоплазии
US5527775A (en) Reduction of mammalian neoplasms with phospholipase A2 activating substances
EP1626990A1 (en) Immunotherapy of rectal cancer
CN105194663A (zh) 聚乙二醇化磷脂为载体的胶束多肽疫苗
CN113278634B (zh) 一种预防和治疗默克尔细胞癌的新型疫苗
US20050180947A1 (en) Novel application of vaccination against TNF-alpha
JP5960064B2 (ja) ヒトプロガストリンペプチドに対する免疫原性組成物
CN101061136A (zh) 具有白介素－2中和能力的免疫治疗制剂
EP1027071A2 (en) Encapsulated immunomodulators useful as vaccine adjuvants
JPH08225462A (ja) ワクチン
AU2003200723B2 (en) Encapsulated immunomodulators useful as vaccine adjuvants

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20040714

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND INVENTORS NAMES TO INCLUDE: STACY M PLUM